Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b randomized double-blind placebo-controlled study of TRC101 in chronic kidney disease with metabolic acidosis
MOH_2019-01-14_004856Phase 3Completed
- Sponsor
- Tricida, Inc.
- Start
- Nov 2018
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing TRC101 with Placebo (2 arms). Started Nov 2018; status: completed.
02
Drugs
veverimer
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on MOH_2019-01-14_004856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-14_004856.